Story perspectives

Japan Approves Groundbreaking Stem-Cell Therapies for Parkinson's and Heart Failure

3/6/2026

Summary

Story summary

Japan approved two stem-cell therapies, Amchepry for Parkinson's and ReHeart for severe heart failure, with availability by summer 2026.
Amchepry, developed by Sumitomo Pharma, transplants stem-cell-derived cells into the brain to restore dopamine.
ReHeart, created by Cuorips, uses sheets of heart muscle cells to improve cardiac function.
They are the first therapies to use induced pluripotent stem (iPS) cells, a technology by Nobel Prize-winning scientist Shinya Yamanaka.

1 of 1

Story summary

Japan approved two stem-cell therapies, Amchepry for Parkinson's and ReHeart for severe heart failure, with availability by summer 2026.
Amchepry, developed by Sumitomo Pharma, transplants stem-cell-derived cells into the brain to restore dopamine.
ReHeart, created by Cuorips, uses sheets of heart muscle cells to improve cardiac function.
They are the first therapies to use induced pluripotent stem (iPS) cells, a technology by Nobel Prize-winning scientist Shinya Yamanaka.